BioSpace News Archive

Bolt Biotherapeutics announced that management will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022, at 12:45 p.m. PT.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

ILIAS Biologics Inc., announced today that it has received approval by the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1, the first-in-human trial of ILB-202, exosome therapeutics for the treatment of cardiac surgery-associated acute kidney injury (AKI).

Sherlock Biosciences today announced that industry veteran Karen Davies has been appointed to its executive team as Chief Development Officer.

Trevi Therapeutics, Inc. announced that it has entered into a definitive agreement with certain healthcare-focused institutional investors for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 4,580,526 shares of common stock at a purchase price of $1.90 per share, and pre-funded warrants to purchase up to an aggregate of 24,379,673 shares of common stock at a purchase price of $1.899 per warrant, for gross proceeds of approximately $55 million.

Ardelyx, Inc. today announced multiple presentations covering additional positive clinical observations of XPHOZAH at the National Kidney Foundation 2022 Spring Clinical Meetings (NKF SCM2022), which is taking place in Boston, MA from April 6-10, 2022.

Harmony Biosciences Holdings, Inc. is now accepting applications for the second annual Progress at the Heart program, which funds innovative programs that address disparities, injustice, and inequities in the rare neurological disease and sleep disorder communities.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2022 financial results on Thursday, April 28, 2022 after the close of U.S. financial markets.

Bicycle Therapeutics plc today announced updated preclinical results providing further evidence for Bicycles as a potential novel antiviral modality against SARS-CoV-2.

Saranas announced its Early Bird Bleed Monitoring System has received an Innovative Technology contract from Vizient, Inc., the nation’s largest member-driven health care performance improvement company.